Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbvie (NYSE: ABBV) following Q4 results but lowered his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE